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Small-molecule library screening to find com-
pounds that inhibit TNFa-induced, but not inter-
leukin 1b (IL-1b)-induced, intercellular adhesion
molecule 1 (ICAM-1) expression in lung epithe-
lial cells identified a class of triazoloquinoxa-
lines. These compounds not only inhibited the
TNFa-induced nuclear factor kB (NFkB) survival
pathway but also blocked death-pathway acti-
vation. Such dual activity makes them unique
against other known NFkB-pathway inhibitors
that inhibit only a subset of TNFa signals leading
to increased TNFa-induced cytotoxicity. Inter-
estingly, these compounds inhibited associa-
tion of TNFa receptor (TNFaR) I with TNFaR-
associated death domain protein (TRADD) and
receptor interacting protein 1 (RIP1), the initial
intracellular signaling event following TNFa
stimulation. Further study showed that they
blocked ligand-dependent internalization of the
TNFa-TNFaR complex, thereby inhibiting most
of the TNFa-induced cellular responses. Thus,
compounds with a triazoloquinoxaline scaffold
could be a valuable tool to investigate small
molecule-based anti-TNFa therapies.
INTRODUCTION
TNFa is one of the earliest cytokines to be secreted into the
site of inflammation in various cell types [1, 2]. TNFa exerts
its multiple functions through two structurally related
cell-surface receptors, p55 (type 1 receptor; TNFaRI,
CD120a) and p75 (type 2 receptor; TNFaRII, CD120b) [3].
Whereas TNFa receptor (TNFaR) I is known to mediate
the majority of TNFa-induced cellular events, TNFaRII ap-
pears to have unique and overlapping roles, although this
remains the subject of ongoing research [4]. Upon ligand
binding, TNFaRI recruits at least two death domain-con-
taining proteins, TNFaR-associated death domain protein
(TRADD) and receptor interacting protein 1 (RIP1), as well
as E3 ubiquitin ligases, TNF receptor-associated factorChemistry & Biology 14, 1105–111(TRAF) 2, and TRAF5, to form a large signal-initiating com-
plex [5]. TRAF2 andTRAF5 are functionally redundantmol-
ecules and play a vital role in bridging the TNFaRI complex
eventually to trigger nuclear factor kB (NFkB) and stress
pathways, both of which are important regulators of cell
survival and gene expression [2, 6]. In contrast, TRADDas-
sociates with Fas-associated death domain (FADD) in or-
der to send a signal to the caspase-dependent death path-
way [7]. The balancebetween survival anddeath pathways
appears to determine cell fate and is influenced by the cel-
lular context as well as coexisting extracellular signals.
From the perspective of inflammation, activation of the
NFkB pathway is considered to be a key step, as NFkB-
mediated transcription strongly amplifies the magnitude
of inflammation throughproduction of proinflammatory cy-
tokines, chemokines, and cell-adhesion molecules [8]. As
a result, tissue-infiltrating cells (e.g., neutrophils and mac-
rophages) are attracted to the site of inflammation and
cause tissue damage. Knockout or pharmacological inhi-
bition of TNFa by neutralizing antibodies or soluble recep-
tors has been shown to greatly diminish the progression of
inflammation in various animal models as well as in human
diseases, highlighting TNFa as a good drug target [9].
Despite the clinical success of protein-based drugs
against TNFa, development of small-molecule TNFa
inhibitors has not been very successful [9]. Reported
small-molecule TNFa antagonists include inhibitors of
the processing enzyme TACE [10], disruptors of TNFa tri-
merization [11], and disruptors of ligand-receptor interac-
tion [12]. There have also been notable advances in the
development of small-molecule inhibitors for intracellular
signaling pathways of TNFa [13–17]. However, inhibition
of the NFkB pathway by small molecules may require
careful evaluation with regard to potential tissue toxicities,
particularly in the liver. This concern has been raised partly
by phenotypes of IKKb knockout mice or several other
molecules in the NFkB pathway (e.g., RelA) in which in-
creased apoptosis of liver cells was observed [18–21].
As inactivation of IKKb did not affect the TNFa-induced
death pathway, it is possible that liver toxicity was a result
of enhanced TNFa-induced cytotoxicity. In fact, small-
molecule inhibitors of IKKb or proteasome that prevent
IkB degradation and thus inhibit the NFkB pathway have
been shown to increase TNFa-induced cytotoxicity [22,
23]. A stress-pathway kinase, p38 MAPK, has also been8, October 2007 ª2007 Elsevier Ltd All rights reserved 1105
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companies, yet its progress has been delayed partly due
to toxicity in the liver [9]. Moreover, NFkB and stress path-
ways are activated not only by TNFa but also by numerous
other cytokine receptors, toll-like receptors (TLRs), and
immune-cell receptors [24–26]; it is thereforechallenging to
achieve sufficient selectivity to limit potential side effects.
Given such challenges, we initiated this study to identify
small molecules that specifically inhibit all TNFa functions.
As both TNFa and interleukin 1b (IL-1b) activate NFkB and
stress pathways leading to the upregulation of intracellular
adhesion molecule 1 (ICAM-1) expression in A549, a lung
epithelial cell line, we used changes in ICAM-1 expression
as a readout, and looked for compounds that inhibited
TNFa-induced signaling more efficiently than IL-1b. En-
zyme-linked immunosorbent assay (ELISA)-based high-
throughput screening (HTS) of 300,000 in-house com-
pounds in such a differential cell-based assay identified
a class of compounds that had a core structure of triazo-
loquinoxaline (TQ). Detailed mechanistic studies demon-
strated that TQ compounds inhibit virtually all signaling
pathways activated by TNFawithout perturbing ligand-re-
ceptor interaction at potencies as low as submicromolar.
We further provide evidence that TQ compounds inhibit
endocytosis-dependent formation of the TNFaRI-signal-
ing complex. Our findings show that these TQ compounds
are capable of inhibiting most, if not all, TNFa functions
through a unique mechanism of action.
RESULTS
Compound Screening and Hit Identification
As a number of cytokines, including TNFa and IL-1b, are
known to activate NFkB and stress pathways (Figure 1A),
inhibition of these pathways is unlikely to be specific to-
ward TNFa. It was expected that numerous compounds
in our library would inhibit these pathways and thus
overshadow real ‘‘TNFa-specific’’ hits. Therefore, we em-
ployed a differential screening strategy to identify com-
pounds that inhibited TNFa but not IL-1b-induced signals
using ICAM-1 induction as a common cellular readout.
ELISA-based HTS of 300,000 compounds was carried
out at 10 mM in A549 lung epithelial cells following a 5 hr
incubation with TNFa and IL-1b. The coefficient of
variation (CV) and the Z0 factor for our HTS assay were
found to be within the acceptable range (CV = <5% and
Z0 factor = 0.885). Primary hits that fulfilled the following
two criteria were promoted for EC50 determination: (1) at
least 60% reduction of ICAM-1 expression induced by
TNFa, and (2) significantly lower inhibition of ICAM-1
induced by IL-1b (greater than 30% difference in percent
inhibition). Among those tested for EC50, compoundsChemistry & Biology 14, 1105–11that reproducibly showed 1.5-fold or greater potency to-
ward TNFa over IL-1b were nominated for further analysis
including analog testing. Finally, TNFa-selective hits were
confirmed for their activity in various bioassays such as
production of IL-6 and IL-8, as well as a reporter assay
using a 50-transcriptional regulatory region of IL-8 (data
not shown). All of the above analyses finally resulted in
identification of two structurally related small-molecule
compounds that had triazoloquinoxaline as a core struc-
ture (Tables 1A and 1B). Among them, R-7050, 8-chloro-
4-(phenylthio)-1-(trifluoromethyl)-[1,2,4]triazolo[4,3-a] qui-
noxaline, emerged as a potent and fully reversible hit with
greater selectivity toward TNFa. Figure 1B shows typical
inhibition curves obtained for some of the active and inac-
tive hits along with standard positive controls such as
IKK2-VI andMG132. In TNFa-induced ICAM-1 expression,
R-7050 inhibition potency (EC50 = 0.63mM)was 2- to 3-fold
greater than EC50 for IL-1b-induced ICAM-1 expression
(1.45 mM). As shown in Tables 1A and 1B, a fewmore addi-
tional TQcompoundswere identified through thesubstruc-
ture search, and we found that none of them were more
potent than original hits, following EC50 determination.
Based on structure-activity-relationship (SAR) analysis,
R-7050 contained important substituents on either side of
the core heterocyclic ring structure that were critical for
inhibitory activity. Also, the potency depends on the pres-
ence of chlorine substituents as well as electron-with-
drawing groups such as unsubstituted phenyl, pyridine,
and pyrimidine moieties. For example, the absence of
chlorine (R1 substituent) and the presence of electron-do-
nating groups such as methoxyphenyl (R3) in the case of
R-7075 and R-7082 completely eliminated the inhibitory
activities for these compounds. Similar observations
were also made in the case of a second group of com-
pounds derived from triazoloquinoxalines which lack the
phenylthio substituent (Table 1B). Substitution of the
trifluoromethyl group in both classes of triazoloquinoxa-
lines (R2 in the case of Table 1A) was found to enhance
the inhibitory activity. However, no clear effect of elec-
tron-withdrawing groups was noted, and multiple me-
thoxy substituents were no prerequisite for increased
inhibitory activity (data not shown). For further evaluation
including target identification and mechanism of action
studies, R-7050, R-8507, and its inactive counterpart
R-7082 were selected.
Effect on TNFa-Induced NFkB and Stress-Pathway
Activation
In order to investigate the mechanism/target of action of
TQ compounds, we examined their effects on phosphory-
lation, ubiquitination, and degradation of intracellular sig-
naling proteins. One of the major pathways activated byFigure 1. Activation of Key Signaling Pathways upon TNFa and/or IL-1b Stimulation and Measurement of ICAM-1 Expression as
a Functional Readout
(A) Schematic of TNFa and IL-1b signaling pathways showing key members and potential sites of inhibition.
(B) Representative inhibition curves and EC50 values obtained for triazoloquinoxaline hits in the ELISA-based ICAM-1 induction assay. Two known
inhibitors, IKK2-VI and MG132, that inhibit TNFa and IL-1b signals at equal potency were included for reference. Numbers at the bottom represent
ratios of EC50 values. A higher number denotes greater selectivity of hits toward TNFa-induced ICAM-1 expression over IL-1b. 9999 indicates that the
compound is inactive. Error bars are standard deviations of the mean of at least three replicates.18, October 2007 ª2007 Elsevier Ltd All rights reserved 1107
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A
Compound ID R1 R2 R3 Molecular Weight
ICAM-1 ELISA EC50 (mM)
TNFa IL-1b IL-1b/TNFa
R-7050 Cl CF3 380.78 0.631 1.452 2.30
R-7078 H CF3 380.78 0.721 1.612 2.23
R-7081 H CF3 346.33 1.921 3.612 1.88
R-7080 H CF3 347.32 4.072 7.174 1.76
R-7047 H H 280.31 7.561 8.034 1.06
R-7075 H H 308.36 >1000 >1000 na
R-7082 H CF3 376.36 >1000 >1000 na
B
Compound ID R Molecular Weight
ICAM-1 ELISA EC50 (mM)
TNFa IL-1b IL-1b/TNFa
R-8507 348.71 2.451 3.792 1.541108 Chemistry & Biology 14, 1105–1118, October 2007 ª2007 Elsevier Ltd All rights reserved
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Compound ID R Molecular Weight
ICAM-1 ELISA EC50 (mM)
TNFa IL-1b IL-1b/TNFa
R-8525 328.29 5.123 8.123 1.59
R-8520 340.31 8.451 12.11 1.43
R-8515 332.26 14.23 19.83 1.39
R-8522 393.71 23.72 >1000 na
R-8510 253.18 >1000 >1000 na
R-8516 382.27 >1000 >1000 na
The anti-ICAM-1 expression activities represent an average EC50 value derived from ICAM-1 ELISA assays carried out in duplicate
on different days separately. na, not available.TNFa is the NFkB pathway and, in fact, the 50-regulatory
region of the ICAM-1 gene contains multiple functional
NFkB binding sites [27]. Phosphorylation and ubiquitina-
tion of IkBa by IKKb and Skp1-Cullin-F box protein
(SCFbTRCP), respectively, are prerequisites for NFkB to
be released from its inhibition and to translocate into the
nucleus to activate various genes including ICAM-1 [8,
28]. We found that the active TQ compounds R-7050
and R-8507 inhibited degradation of IkBa only when cells
were stimulated with TNFa, not with IL-1b, andmaintained
the IkBa protein at a similar level as an IKKb inhibitor
(IKK2-VI) (Figure 2A). In contrast, an inactive analog of
TQ compounds (R-7082) had no effect even at 10 mM,
and IkBa was rapidly degraded upon stimulation (data
not shown). In a similar concentration range, active TQ
compounds were able to inhibit phosphorylation and
ubiquitination of IkBa in a TNFa-specific manner (Fig-
ure 2B). Consistently, translocation of NFkB into the nu-
cleus which occurs following IkBa degradation was
blocked by the active TQ compound R-7050 (Figure 2C).
These results indicate that TQ compounds inhibit the
NFkB pathway and that the target of action is most likely
to be upstream of IKKb.
We next examined the effect of TQ compounds on the
phosphorylation status of stress-pathway kinases. A
panel of phosphoblot analysis shown in Figure 2D indi-
cated that R-7050 inhibited phosphorylation of both the
c-Jun N-terminal kinase (JNK) pathway (MKK4, JNKs,
and ATF2) and p38 pathway (MKK3/6, p38, and MAP-
KAP2), although to different degrees. It was noted thatChemistry & Biology 14, 1105–1phosphorylation of JNK-pathwaymolecules was relatively
more sensitive to R-7050-mediated inhibition than to p38-
pathway inhibition. This phenotype is reminiscent of those
in TRAF2 knockoutmice or in cells transfectedwith TRAF2
siRNA [29, 30] in which activation of JNK by TNFa was
more affected than p38 activation, implying that the target
of TQ compounds is either TRAF2 itself or further up-
stream in the TNFa signaling pathway.
Effect on TNFa-Induced Apoptosis Pathway
It is known that there are at least two types of TNFa-re-
sponsive cells: one is resistant to TNFa-induced death
mainly due to efficient activation of the NFkB pathway
and the other is relatively more sensitive and is killed by
TNFa, which is further enhanced in the presence of pro-
tein- or RNA-synthesis inhibitors including cycloheximide
or actinomycin-D (Act-D). Such sensitive cells, such as
ME180 and BT-20, have been used for the study of TNFa-
induced cytotoxicity and caspase activation [31]. Hence,
we took advantage of ME180 cells to address whether TQ
compounds could block TNFa-induced death-pathway
activation.
When treated with increasing concentrations of TNFa
alone, ME180 cells showed a significant, yet not striking,
downward trend in cell survival (Figure 3A). In the presence
of either Act-D or NFkB-pathway inhibitors IKK2-VI or
MG132, TNFa-induced cytotoxicity was greatly enhanced
(Figure 3A). In clear contrast, active TQ compounds (R-
7050, R-8507, andR-7078) prevented the downward trend
incell survival in thepresenceof TNFa, althoughadditionof118, October 2007 ª2007 Elsevier Ltd All rights reserved 1109
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Pathway Activation
(A) Western blot analysis of IkBa degradation when cells were stimu-
lated with TNFa or IL-1b for 20 min in the presence or absence of var-
ious concentrations of R-7050. Lower bands are IkBa-specific signals.
R-7050 shows clear TNFa-specific inhibition of IkBa degradation in
a dose-dependent manner.
(B) IkBa phosphorylation and ubiquitination in cells stimulated with
TNFa for 5 min in the presence of various concentrations of active
(R-7050 and R-8507) or inactive (R-7082) compound. Whereas active
compounds inhibited both phosphorylation and ubiquitination of IkBa,
an inactive compound did not. Protein levels of IkBa did not change at
this time point (5 min), indicating that a decrease in phosphorylation
and ubiquitination of IkBa was not a result of protein degradation.
Different anti-IkBa antibodies were used in (A) (monoclonal) and (B)
(polyclonal), because a ubiquitinated form of IkBawas detected better
with the polyclonal antibody.
(C) Image-based NFkB translocation assay data derived from HeLa
cells stimulated with TNFa or IL-1b for 30 min in the presence or ab-
sence of R-7050 (5 mM) or IKK2-VI (10 mM), and intracellular NFkB
was detected with a rabbit anti-NFkB p65/Alexa Fluor 488-conjugated
goat anti-rabbit IgG antibody pair. Note that TQ compounds specifi-1110 Chemistry & Biology 14, 1105–1118, October 2007 ª200these compounds alone reduced celltiter-glo reading to
some extent (Figure 3B). There was no clear effect by
R-7082, an inactive TQ compound analog. Apparent re-
duction in celltiter-glo reading by R-7050/R-7082/R-8507
alone is probably due to their mild cytostatic effect; how-
ever, it is unlikely that the anti-TNFa activity of these com-
pounds is an indirect consequence of the cytostatic effect,
because TNFa-induced cytotoxicity usually does not re-
quire cell proliferation. In agreement with these results, ac-
tivation of caspase3/7 by TNFawas reduced by active TQ
compounds but not by the inactive analogR-7082 (Figures
3E–3G). Furthermore, neither was Fas- nor C6-ceramide-
induced cell death inhibited by TQ compounds (Figures
3C and 3D). These stimuli are known to directly activate
theFADD-dependent or downstreamcaspasepathway in-
dependently of TRADD, eliminating the possibility that the
target of TQ compounds is the FADD- or caspase-depen-
dent pathway. These results, alongwith data shown in Fig-
ures 2 and 3, suggested that the mechanism of action for
TQ compounds was the interference of signaling events
proximal to TNFaRI.
TQ Compounds Inhibit Interaction between
TNFaRI, RIP1, and TRADD
The initial event after ligand-induced TNFaRI trimerization
is recruitment of a death domain (DD)-containing adaptor
molecule, TRADD. TRADD in turn recruits at least two
other signalingmolecules, RIP1 andTRAF2, to forma large
molecular weight complex, prompting us to speculate that
the formation of this complex was interfered with by TQ
compounds. We therefore addressed this question by
conducting an immunoprecipitation experiment using an
anti-TNFaRI antibody. Lysates from A549 cells treated
with TNFa for 20 min in the presence or absence of TQ
compounds were immunoprecipitated with an anti-
TNFaRI antibody and the presence of TRADD and RIP1
in immunoprecipitates was examined by western blot
analysis. Clearly, TNFaRI failed to associate with either
TRADD or RIP1 in the presence of active TQ compounds
(R-7050 and R-8507), whereas the complex remained in-
tact when an inactive TQ compound (R-7082) was used
(Figure 4A). The range of effective concentrations was
similar to those observed in other assays, suggesting
that the prevention of complex formation was indeed
a cause of inhibition of downstream pathways.
TQ Compounds Block Internalization of the TNFa
Ligand-Receptor Complex
Although formation of the TNFaRI-TRADD-RIP1 complex
was inhibited by TQ compounds, analyses of crystal
structures of TNFaRI and other DD-containing proteins in-
cluding TRADD demonstrated that such an interaction is
cally inhibited TNFa-induced NFkB translocation to the nucleus,
whereas IKK2-VI inhibited both.
(D) Phosphoblot analysis of stress-pathway kinases following TNFa or
IL-1b stimulation (20 min). R-7050 inhibited phosphorylation of these
kinases in a TNFa-specific manner. JNK-pathway members appeared
to be more sensitive to TQ compounds than p38 MAPK-pathway
members.7 Elsevier Ltd All rights reserved
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(A–D) Inhibition of TNFa-induced cytotoxicity by TQ compounds. TNFa-sensitive ME180 cells were treated with increasing concentrations of
TNFa (A and B), Fas- (C), or C6-ceramide (D) for 24 hr in the presence of various inhibitors: IKK2-VI and MG132 (NFkB-pathway inhibitors), Actino-
mycin D (an RNA-synthesis inhibitor), MDC (an endocytosis inhibitor), or TQ compounds identified in this study. TQ compounds inhibited TNFa-
induced, but not Fas- or C6-ceramide-induced, cytotoxicity. Error bars are standard deviations of the mean of at least three replicates.
(E–G) Effect of TQ compounds on TNFa-induced caspase3/7 activation. Test compounds were added to ME180 cells stimulated with TNFa in the
presence (E and G) or absence (F) of MG132 for 24 hr, and caspase3/7 activity in cell lysates was measured by a caspase3/7 assay kit. A cell-perme-
able caspase inhibitor, Z-VAD-fmk, was used as a positive control. TQ compounds inhibited TNFa-induced caspase3/7 activation regardless of the
presence or absence of MG132, although the level of inhibition was lower than that of Z-VAD-fmk. Error bars are standard deviations of the mean of at
least three replicates.highly rigid and their conformational spaces are extremely
limited [32, 33]. Interestingly, it has been suggested that
formation of the functional TNFaRI-signaling complex
requires its internalization upon ligand binding via the clas-
sical clathrin-dependent receptor-mediated endocytotic
pathway [34]. Therefore, we investigated the effect of TQ
compounds on internalization of the TNFa-TNFaR com-
plex by an indirect immunofluorescence staining method
[35]. Biotinylated TNFa was added to the culture in the
presence or absence of a TQ compound (R-7050) or
monodansylcadaverine (MDC), and the cellular distribu-
tion of the ligand-receptor complex was analyzed using
a fluorescence microscope after staining with fluorescein
isothiocyanate (FITC)-avidin. In the absence of an inhibi-
tor, TNFa binding on the cell surface at 4C showed a uni-
form distribution of the ligand-receptor complex through-
out the plasma membrane (Figure 5A). Upon shifting theChemistry & Biology 14, 1105–11temperature to 37C, the fluorescence intensity became
more condensed and perinuclear staining due to colocal-
ization at lysosomal compartments became more promi-
nent during the period of incubation up to 1 hr. This ap-
peared to be the typical process of ligand-induced
TNFaR internalization, and the kinetics of intracellular
staining is in good agreement with previous observations
[36, 37]. In the presence of R-7050, translocation of the
ligand-receptor complex to perinuclear and lysosomal
compartments was efficiently prevented and the staining
remained uniform on the plasma membrane similar to
that in unstimulated cells. Similarly, MDC prevented inter-
nalization of the ligand-receptor complex. Although this
assay does not distinguish between TNFaRI and TNFaRII,
it is clear that TNFa was retained on the plasma mem-
brane in the presence of a TQ compound (R-7050) regard-
less of receptor subtypes.18, October 2007 ª2007 Elsevier Ltd All rights reserved 1111
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mation of the TNFaRI-TRADD-RIP1
Complex
(A) TQ compounds prevent formation of the
TNFaRI-TRADD-RIP1 complex. A549 cells
were stimulated with TNFa in the presence
of active (R-7050 and R-8507) or inactive (R-
7082) compound for 20 min. TNFaRI was im-
munoprecipitated and the presence of TRADD
and RIP1 in the immune complex was assayed
by western blots. TNFa-induced association of
TRADD and RIP1, preferably in its ubiquiti-
nated form, with TNFaRI was inhibited by
active, but not by inactive, compounds.
(B) MDC, a known endocytosis inhibitor, also
inhibited TNFa-induced association between
TNFaRI, TRADD, and RIP1. Upper bands in
the TRADD blots are presumably multimerized
forms of TRADD (M-TRADD).Finally, we addressed whether known internalization in-
hibitors were capable of inhibiting TNFa-mediated signals
specifically over IL-1b signals. We carried out a differential
ICAM-1 assay for two of known inhibitors for endocytosis;
one is a clathrin-dependent endocytosis inhibitor, MDC
[35], and the other is a nonspecific endocytosis inhibitor,
phenylarsenic oxide (PAO) [38] (Table 2). As expected,
MDC showed TNFa-skewed activity with an IL-1b/TNFa
EC50 ratio of 2.26, whereas PAO had a marginal 1.68 ratio
that was still higher than those obtained for IKK2-VI or
MG132 that inhibited TNFa- and IL-1b-induced ICAM-1
with similar potency (a ratio of 0.9:1.2). As it has been re-
ported that a subset of TNFa-induced signaling requires
localization of TNFaRI into a lipid raft, a membrane micro-
subdomain enriched in cholesterol and sphingolipid [39,
40], we tested a disruptor of lipid rafts, methyl-b-cyclo-
dextrin (MCD), and found that there was not much differ-
ence in EC50 between TNFa- and IL-1b-mediated ICAM-
1 production (Table 2). To further assess the selectivity
of TQ compounds against other receptor systems, we ex-
amined the effect of R-7050 on phosphorylation of JNK
and AKT used as surrogate assays induced by EGF [41],
IGF-1 [42], insulin [43], and lysophosphatidic acid (LPA)
[44] to indirectly monitor ligand-induced receptor internal-
ization. Figures 5B and 5C show that a TQ compound
(R-7050) exhibited inhibitory effects only in TNFa and
LPA receptor systems, but not in IL-1bR, InsulinR, IGFR,
or EGFR. In contrast, MDC inhibited endocytosis of
most of the receptor systems tested. Taken together, we
conclude that inhibition of internalization of the TNFa-
TNFaR complex was, at least in part, the mechanism of
action of TQ compounds.
DISCUSSION
Our high-throughput screening aimed at TNFa inhibitors
identified a class of small molecules that contained
a core structure of TQ. These compounds inhibited TNFa-
induced ICAM-1 expression more efficiently than IL-1b-
induced ICAM-1 in the same cell type (A549, human lung
epithelial cells). It has also been reported that TQ com-1112 Chemistry & Biology 14, 1105–1118, October 2007 ª2007pounds inhibit cytokine-induced ICAM-1 expression [45];
however, there has been no study on cytokine selectivity
or detailed mechanism of action for these compounds.
Our results described below demonstrated that TQ com-
pounds specifically inhibit TNFa-induced signaling path-
ways and subsequent biological functions by preventing
the formation of the TNFaRI-signaling complex. During
this study, we also found that many of the compounds
that inhibited TNFa- and IL-1b-induced ICAM-1 at a similar
potency had NFkB-pathway inhibitory activity (data not
shown). This was not surprising, because both TNFa
and IL-1b are known to activate the NFkB pathway in
A549 cells. Thus, our simple differential screening system
appeared to be robust in pulling out TNFa-selective hits
from our 300,000-compound library. By a similar differ-
ential screening approach, we previously isolated specific
inhibitors for the spleen tyrosine kinase (Syk) [46, 47].
These compounds are currently being evaluated in multi-
ple clinical trials for treating immunological disorders and
cancer. Accordingly, our cell-based differential screening
is efficient in identifying selective compoundswith reason-
able potency for drug development.
Detailed biological profiling studies revealed that TQ
compounds selectively inhibited most, if not all, of the sig-
naling pathways induced by TNFa that are involved in cell
survival and gene expression (NFkB and stress pathways)
as well as caspase-dependent death pathways. It is
a striking property, because many of the reported inhibi-
tors for TNFa are able to inhibit only a subset of signaling
pathways. For example, inhibitors for IKKs inhibit phos-
phorylation and degradation of IkBa and subsequent
NFkB translocation, DNA binding, and transcriptional
activation [48]. However, these inhibitors do not inhibit
TNFa-induced death-pathway activation and rather en-
hance its cytotoxicity, correlating with phenotypes of
IKKb knockout mice. In these mice, massive apoptosis
was observed particularly in the liver [18–20] as well as
in the skin of the conditional knockout model [49].
Although such defects in the liver were observed mainly
during development, conditional inactivation of the NFkB
pathway in adult hepatocytes resulted in enhancedElsevier Ltd All rights reserved
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Small-Molecule TNFa AntagonistsFigure 5. Effect of TQ Compounds on Internalization of the TNFa Ligand-Receptor Complex and Its Selectivity toward Other
Nonrelated Ligand-Receptor Internalization Activities
(A) Subcellular localization of the TNFa-TNFaR complex. A549 cells stimulated with biotinylated TNFawere fixed at indicated time points and stained
with FITC-labeled avidin. Both R-7050 and MDC inhibited TNFa-induced internalization of the TNFa-TNFaR complex.
(B and C) Selectivity of a TQ compound (R-7050) and a known receptor internalization inhibitor (MDC) over other nonrelated ligand-receptor internal-
ization-mediated signaling events measured by phospho-JNK ELISA (B) and phospho-AKT ELISA (C) as a cellular functional readout. A549 cells
seeded onto a six-well plate were serum starved overnight and preincubated with R-7050 (5 mM) and MDC (100 mM) for 1 hr at 37C before ligand
stimulation for 10 min. Cell-lysate preparation and phospho-JNK/AKT sandwich ELISA was carried out as described in the assay kits (Cell Signaling
Technology). Error bars are standard deviations of the mean of at least three replicates.apoptosis upon TNFa administration in vivo [50]. This
property of these compounds can be problematic when
they are used systemically for human immunological dis-
eases that often require long-term treatment. The liver tox-
icity appears to be not only limited to IKK inhibition, be-
cause knockout models for JNK and SEK1/MKK4,
stress-pathway kinases, also showed increased cell death
in liver cells [51]. In this context, simultaneous inhibition of
both death and survival pathways seems to bemore desir-
able. Our compounds inhibited caspase activation and
subsequent cell death in addition to NFkB and stress
pathways. Besides the selectivity over IL-1b inhibition,Chemistry & Biology 14, 1105–11TQ compounds prevented cell death induced by TNFa,
but not by Fas- or C6-ceramide, extending their selectivity
over other death-inducing signals. This is another de-
sirable feature of this class of compounds, because
nonspecific inhibition of cell death in vivo could result in
hyperplasia, neoplastic transformation, or generation of
self-reactive immune cells [52].
The fact that TQ compounds inhibited most of the TNFa
signaling led us to consider that the target of action for TQ
compounds could be in the proximity of TNFaRI or
TRADD. It has been suggested that TRADD is the point
where survival and death pathways are bifurcated through18, October 2007 ª2007 Elsevier Ltd All rights reserved 1113
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or Lipid Rafts (MCD)
Compound (ID)
TNFa IL-1b Ratio
EC50 (mM) EC50 (mM) IL-1b/TNFa
Triazoloquinoxaline (R-7050) 0.631 1.45 2.30
Monodansylcadaverine (MDC) 61.52 139 2.26
Phenylarsenic oxide (PAO) 0.47 0.79 1.68
Methyl-b-cyclodextrin (MCD) 1923 2482 1.29
EC50 = effective concentration for 50% inhibition.
A detailed assay protocol is described in Experimental Procedures.association with at least two proteins, FADD and TRAF2,
on distinct regions of TRADD [1, 7]. FADD associates
with a C-terminal death domain of TRADD and transmits
a signal to the downstream death pathway. Deletion of
the FADD-associating region on TRADD or pharmacolog-
ical inhibition of the downstream caspase pathway inter-
feres with TNFa-induced cytotoxicity, whereas activation
of the NFkB or stress pathways was relatively unaffected
[7]. In clear contrast, TRAF2 associates with a non-DD re-
gion on the N-terminal half of TRADD, independently of
FADD, and leads to activation of the NFkB and stress
pathways [5, 7]. Meanwhile, TNFa-induced cell death
was greatly enhanced in TRAF2 and TRAF2/TRAF5
double knockout mice, suggesting that only a survival
pathway was perturbed by deletion of TRAF2 [29]. More-
over, inactivation of other molecules associating with the
TNFaRI complex or in downstream pathways such as
RIP1, TAK1, IKKb, and RelA has been shown to increase
sensitivity to TNFa-induced cell death [1, 3]. On the other
hand, knockout of TNFaRI and expression of dominant-
negative TRADD inhibited both survival and death path-
ways following TNFa challenge [34, 37]. Because the TQ
compounds did not inhibit ligand-receptor interaction at
all (data not shown), the most likely target for TQ com-
pounds is in close proximity to the TNFaRI complex.
Our immunoprecipitation analysis clearly showed that
formation of the TNFaRI complex was interrupted by TQ
compounds. The TNFaRI-TRADD complex is formed by
the interactions of DD on both TRADD and TNFaRI. As nei-
ther TNFaRI nor TRADD has been shown to have any con-
siderable enzymatic activity, we first speculated that the
mechanism of action by TQ compounds was inhibition
of complex formation. However, crystal structure analysis
of DD-containing proteins demonstrated that an individual
DD has a very compact a helix bundle-based structure
and forms an extremely rigid quaternary structure through
surface-surface interaction [32, 33]. It seemed unlikely
that a DD-mediated protein complex has wide enough
space for a small molecule to prevent or disrupt its forma-
tion. Interestingly, it is known that at least two more phys-
iological steps are required for TNFaRI to form a functional
signaling complex, that is, receptor internalization and
compartmentalization, to the plasma membrane micro-
subdomain called a lipid raft [39, 40]. We showed that1114 Chemistry & Biology 14, 1105–1118, October 2007 ª2007TQ compounds were able to inhibit TNFa-induced inter-
nalization of the TNFa-TNFa receptor complex. Moreover,
known internalization inhibitors MDC and PAO showed
TNFa-skewed activity over IL-1b in our ICAM-1 assay,
whereas the effect of a lipid raft-disrupting reagent
(MCD) was negligible. These results suggest that the
mechanism of action for TQ compounds was prevention
of ligand-dependent internalization of TNFaRI, which is
a prerequisite for recruitment of TRADD. It is known that
there are multiple mechanisms for endocytosis, and that
eachmechanism is differentially involved in various recep-
tor systems [53]. Our data suggest that a TQ compound
(R-7050) has a clear selectivity toward TNFa and to
a slightly weaker extent toward the LPA receptor which
belongs to a GPCR class over IL-1b, tyrosine kinase, or
Fas receptor systems. Therefore, TQ compounds specifi-
cally inhibit a certain mechanism(s) of endocytosis that is
shared with LPA rather than inhibiting global endocytotic
processes, although the exact target is unknown.
Furthermore, TQ compounds have also been studied in
relation to their capability tomodulate subclasses of aden-
osine receptors (ARs) [54]. Because adenosine is known
to participate in regulation of immune systems, typically
through cAMP- and/or Ca2+-dependent signaling path-
ways [55], agents that modulate cAMP (Forskolin and Ro-
lipram) or Ca2+ influx (Ionomycin) did not affect TNFa/IL-
1b-induced IkB degradation or ICAM-1 expression in our
system (data not shown). Therefore, we believe that activ-
ity of TQ compounds on TNFa functions is novel and is not
mediated by modulation of ARs that also belong to
a GPCR class.
In conclusion, we demonstrate a class of small-mole-
cule TNFa antagonists that block most TNFa functions
by inhibition of intracellular events rather than inhibiting li-
gand trimerization or ligand-receptor interaction. Detailed
mechanistic studies indicated that these compounds im-
paired the formation of signal-initiating complexes that
consisted of TNFaRI, TRADD, and RIP1 through inhibition
of ligand-induced receptor endocytosis, which is required
for signaling. Thus, our cell-based screening strategy
allowed us to find inhibitors that broadly inhibited TNFa-
signaling events, and in so doing, to identify a critical link
in a highly complex signaling network that is often redun-
dant. This strategy also uncovered potential modulatorsElsevier Ltd All rights reserved
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which are otherwise difficult to obtain in a cell-free system.
SIGNIFICANCE
The success of protein-based therapy against TNFa
for rheumatoid arthritis and some other immunologi-
cal diseases has provided proof of concept for the
use of anti-TNFa therapy in humans. However, there
are several intrinsic problems with these protein-
based drugs, such as a lack of oral availability, poten-
tial antigenicity, and low tissue-penetrating capabil-
ities. To circumvent such problems, the quest for
small-molecule inhibitors is increasingly growing,
with anticipation to replace protein-based drugs or,
at least, to give physicians and their patients more
options for treatment. In this study, we present a class
of compounds that inhibit both survival (NFkB and
stress pathways) and death pathways induced by
TNFa, mimicking the property of anti-TNFa antibodies
or soluble TNFa receptors that block all of the biolog-
ical functions of TNFa. This activity of compounds is
unique, because many other small-molecule inhibi-
tors, such as IKKb, proteasome, and caspase inhibi-
tors, block only a subset of TNFa-induced signaling
pathways. The mechanism of action of our com-
pounds may not confer perfect selectivity for TNFa,
because several other receptor classes also require
internalization for signaling. However, they were at
least selective over IL-1b-induced signals as well as
over Fas- and C6-ceramide-induced death signaling
pathways besides nonrelated tyrosine kinase receptor
systems. Although further work is necessary to under-
standmore precisely themechanism of action and se-
lectivity over other signals, our observations provide
an important tool to explore the possibility of inhibiting
TNFa signaling with small molecules.
EXPERIMENTAL PROCEDURES
Materials
The following materials were obtained from the indicated sources:
human insulin, monodansylcadaverine (MDC), phenylarsenic oxide
(PAO), methyl-b-cyclodextrin (MCD), actinomycin-D (Act-D), lyso-
phosphatidic acid (LPA), and a proteasome inhibitor (MG132) were
purchased from Sigma (St. Louis, MO, USA). Human TNFa (catalog
number 300-01A), human IL-1b (200-01B), human EGF (100-15), hu-
man IGF-1 (100-11), and human FAS-L (310-03) were from Peprotech
(Rocky Hill, NJ, USA). IKK-b kinase inhibitor IKK2-VI (401483) and cas-
pase inhibitor Z-VAD-fmk (219007) were purchased from Calbiochem
(La Jolla, CA, USA). C6-ceramide (ALX-303-003-M005) was from
Axxora, LLC (San Diego, CA, USA). Mouse anti-CD54 (MHCD5400-
4) was from Caltag Laboratories (Burlingame, CA, USA); rabbit anti-
IkBa (sc-371) and rabbit anti-NFkB p65 (sc-109) were from Santa
Cruz Biotechnology (Santa Cruz, CA, USA); human phospho-SAPK/
JNK ELISA kit (7325), human phospho-AKT ELISA kit (7252), mouse
anti-IkBa (9247), mouse anti-phospho-IkBa (Ser32/36) (9246), rabbit
anti-phospho-MKK4 (Ser257/Thr261) (9156), rabbit anti-phospho-
SAPK/JNK (Thr183/Tyr185) (9251), rabbit anti-phospho-ATF2 (Thr69/
71) (9225), rabbit anti-phospho-MKK3/6 (Ser189/207) (9231), rabbit
anti-phospho-p38 MAPK (Thr180/Tyr182) (9215), rabbit anti-phos-
pho-MAPKAP2 (Thr334) (3047), and rabbit anti-phospho-IKKaChemistry & Biology 14, 1105–11(Ser180)/IKKb (Ser181) (2681) were from Cell Signaling Technology
(Boston, MA, USA); mouse anti-TRADD (610572) and mouse anti-
RIP1 (610458) were obtained from BD Biosciences Pharmingen (San
Diego, CA, USA); goat anti-sTNFR1 (AB-225-PB) was from R&D Sys-
tems (Minneapolis, MN, USA). HRP-conjugated anti-mouse and anti-
rabbit IgG were from Jackson Laboratory (Bar Harbor, ME, USA);
HRP-conjugated anti-mouse IgG2a (02017E) was obtained from BD
Biosciences Pharmingen; and Alexa Fluor 488-conjugated goat anti-
rabbit IgG (A-11008) was from Molecular Probes (Eugene, OR, USA).
All human tumor cell lines used in this study were from the American
Type Culture Collection (Manassas, VA, USA).
High-Throughput Screening
Compounds were dissolved in DMSO at a final stock concentration of
10 mM and stored at –80C. Compound library screening was per-
formed using a fully integrated, programmable robotic liquid handling
system (Biomek FX, Beckman Coulter, Fullerton, CA, USA) with an in-
tegrated plate reader (Accent Fluoroscan, Ramsey, MN, USA) and en-
vironmentally controlled plate carousel set at 37C and 5% CO2. A549
cells (13 104/well) were seeded overnight into 96-well white flat clear-
bottomed plates (Costar, Cambridge, MA, USA) in 100 ml of culture
medium. The next day, 100 ml aliquots from the 300,000-compound
library prepared in the same culture mediumwere added at a final con-
centration of 10 mM in 0.2% (v/v) DMSO. Cells were preincubated with
compounds for 1 hr prior to a 4 hr stimulation with either TNFa or IL-1b
(1 ng/ml final concentration). At the end of the stimulation period, cells
were stained for ICAM-1 using mouse anti-human CD54 monoclonal
antibody (Caltag Laboratories) and HRP-conjugated anti-mouse
IgG2a (BD Biosciences Pharmingen) added together at final dilutions
of 1:1,000 and 1:10,000, respectively. Following 1 hr of incubation at
37C, plates were washed four times using 300 ml PBS and developed
using supersignal ELISA pico chemiluminescent substrate (Pierce,
Rockford, IL, USA). For EC50 determination, cells were stimulated
with either TNFa (25 ng/ml) or IL-1b (10 ng/ml) only for 4 hr to avoid sec-
ondary stimulation by other cytokines produced by the cells.
Image-Based NFkB Nuclear Translocation Assay
One day before the assay, HeLa cells were seeded into 96-well plates
at a density of 2000 cells/well. On the day of assay, cells were preincu-
bated with serially diluted test compounds for 1 hr and stimulated with
either TNFa (25 ng/ml) or IL-1b (10 ng/ml) for 30min at 37C. Cells were
washed twice with PBS and fixed using methanol for 1 hr at room tem-
perature. After blocking the cells with 1%BSA in PBS-Tween 20 buffer
for 1 hr, cells were treated overnight with the same buffer containing
anti-NFkB p65 rabbit polyclonal antibody (1:1000 dilution) followed
by Alexa Fluor 488-conjugated goat anti-rabbit IgG staining (1:1000
dilution) for 3 hr at room temperature using a protocol described pre-
viously [56]. Cells were also costained with 40,6-diamidino-2-phenylin-
dole (DAPI) for 1 hr to track the nuclear morphology. Digital images
were captured using a 103 objective on a Zeiss Axiovert S100 (Carl
Zeiss MicroImaging, Thornwood, NY, USA) microscope equipped
with a UV filter set and a Photometrics (Tucson, AZ, USA) camera.
Cell Death and Viability Assays
Cell viability was assessed using the celltiter-glo luminescent cell via-
bility assay kit from Promega (Madison, WI, USA). TNFa-sensitive
ME180 cells were preincubated with test compounds for 1 hr at
37C and stimulated with various concentrations of TNFa for 24 hr.
At the end of the incubation period, culture media were replaced
with 50 ml of prediluted celltiter-glo reagent (1:1 with PBS) and relative
luminescence intensity was measured using a microtiter plate reader.
Two known NFkB-pathway inhibitors (IKK2-VI and MG132) and an
RNA-synthesis inhibitor (Act-D) known to enhance TNFa-induced cy-
totoxicity were used as controls.
Caspase Assay
The effect of compounds on caspase activity was determined using
the Caspase-Glo 3/7 assay kit (G8091) obtained from Promega.18, October 2007 ª2007 Elsevier Ltd All rights reserved 1115
Chemistry & Biology
Small-Molecule TNFa AntagonistsME180 cells were preincubated with test compounds for 1 hr at 37C
and stimulated with various concentrations of TNFa for 24 hr. At
the end of the incubation period, culture media were replaced with
50 ml of diluted caspase-3/7 reagent (1:1 with PBS) and relative
luminescence intensity was determined following the manufacturer’s
instructions. A proteasome inhibitor, MG132 (known to increase
TNFa-induced cytotoxicity), and a general caspase inhibitor, Z-VAD-
fmk, were used as controls.
Immunofluorescence Analysis of TNFa Receptor
Internalization
This study was carried out as reported by Schutze et al. [35]. Briefly,
HeLa cells were seeded onto 12-well tissue culture plates containing
sterile circular microscope coverslips. Following preincubation of cells
with a test compound or a positive control (MDC) for 1 hr at 37C, the
temperature was shifted to 4C and biotinylated human TNFa (100 ng/
ml) provided in the Fluorokine kit (NFTA0) obtained from R&D Systems
was added to the culture medium. After 2 hr, cells were washed with
PBS to remove unbound TNFa, and biotinylated TNFa-TNFaR com-
plex was allowed to internalize for 10, 30, and 60 min. Cells were
then washed twice with PBS and fixed using cold methanol (90%)
for 30 min. Cells were again washed with PBS and blocked with Super
Block solution (Pierce) containing 0.5% Triton X-100 for 2 hr at room
temperature. Cells were stained with FITC-conjugated avidin (1:50 di-
lution) overnight in the same blocking solution at 4C. Coverslips were
flipped onto glass slides preloaded with a drop of Vecta-shield mount-
ing media (Vector Laboratories, Burlingame, CA, USA). Localization of
the ligand-receptor complex was examined under an Axiovert S100
fluorescence microscope (Carl Zeiss MicroImaging).
Immunoprecipitation of TNFaRI-Associated Signaling
Proteins and Western Analysis
For immunoprecipitation of TNFaRI-associated signaling proteins,
A549 cells (1 3 107 cells in a 10 cm dish) were preincubated with or
without test compounds for 1 hr at 37C and stimulated with TNFa
(50 ng/ml) for 10 min. Following stimulation, cells were washed with
PBS and lysed with 500 ml of RIPA buffer composed of 10 mM Tris
(pH 7.2), 150 mM NaCl, 1% Triton X-100, 1% deoxycholate, 0.1%
SDS, 5 mM EDTA, complete protease inhibitor cocktail, 2 mM sodium
fluoride, and 1mM sodium orthovanadate. Plates were then incubated
for 30 min at 4C and cell lysates were harvested by gently scrapping
off the cells from plates using a cell scraper. After centrifugation
(14,000 rpm, 20 min, 4C), the supernatant was collected and the pro-
tein content was determined using a Micro-BCA protein estimation kit
(Pierce). For the TNFaRI immunoprecipitation experiment, 500 ml of
supernatant was precleared using protein A/G agarose beads (50 ml
of a 50% slurry; Santa Cruz Biotechnology) and incubated with a mix-
ture of goat anti-TNFaRI polyclonal antibody (5 mg) plus 50 ml of protein
A/G agarose beads overnight at 4C with constant end-to-end mixing.
Immune complexes were washed three times with RIPA lysis buffer
and resuspended in the same buffer (50 ml).
Proteins from total cell lysates and immunoprecipitates were boiled
in 43NuPAGE sample buffer containing lithium dodecyl sulfate/dithio-
threitol and subjected to SDS-PAGE (4%–12% bis-Tris gradient gels).
Proteins were electroblotted onto PVDF membranes and probed with
appropriate primary antibodies followed by HRP-conjugated second-
ary antibodies. Blots were then developed using an enhanced chemi-
luminescence plus reagent (AmershamPharmacia Biotechnology, Pis-
cataway, NJ, USA) and detected on Kodak Bio-MAX MR film (VWR
Scientific, San Francisco, CA, USA).
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